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In this article, we will present statistical methods to assess to what extent the
effect of a randomised treatment (versus control) on a time-to-event endpoint
might be explained by the effect of treatment on a mediator of interest, a vari-
able that is measured longitudinally at planned visits throughout the trial. In
particular, we will show how to identify and infer the path-specific effect of
treatment on the event time via the repeatedly measured mediator levels. The
considered proposal addresses complications due to patients dying before the
mediator is assessed, due to themediator being repeatedlymeasured, and due to
posttreatment confounding of the effect of the mediator by other mediators. We
illustrate themethod by an application to data from the LEADER cardiovascular
outcomes trial.
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1 INTRODUCTION
There is a growing interest in statistical analyses that support insight into causalmechanismswhereby an exposure affects
intermediate variables (or mediators), to then in turn produce an outcome. In many such studies, interest lies in one or
more mediators that are measured multiple times during the course of the study. The LEADER trial,1 for instance, eval-
uated the effect of liraglutide (as opposed to placebo), over and above standard care, on time from randomisation to first
major adverse cardiovascular event (MACE) in patients with type II diabetes and high cardiovascular risk, in accordance
with FDA guidelines. Liraglutide is a once-daily injectable drug for the treatment of type II diabetes, commonly branded
as Victoza. A total of 9340 patients were randomised to either of the two treatments with a median follow-up time of
3.8 years. The primary analysis showed a protective effect of randomised assignment to liraglutide on time to first MACE,
amounting to a hazard ratio of 0.87 (95% confidence interval 0.78 to 0.97; this is based on an intention-to-treat analy-
sis, thus not adjusting for time periods off drug, which constituted only a minor fraction of the total patient observation
time). Effects were also seen on other endpoints, eg, glycated haemoglobin levels (HbA1c), blood pressure, body weight,
and urinary albumin to creatinine ratio, which were all repeatedly assessed at fixed time points 3 to 12 months apart.
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The question that motivated this research was to what extent the treatment effect on cardiovascular events is mediated
by these repeatedly measured intermediate variables.
The literature on structural equationmodels provides methods for mediation analysis that can handle multiple, repeat-
edly measured mediators.2 The assumptions are strong, however. Besides relying on linear models without interactions
for all involved outcomes and mediators, untestable additivity assumptions are often made at the individual level. These
assumptions, which are frequently left implicit, state for instance that the effect of treatment while holding the media-
tors fixed is the same for all individuals, which is biologically implausible.3 The causal inference literature on mediation
analysis, pioneered by Robins and Greenland3 and Pearl,4 has explicated these weaknesses and tried to overcome them by
providing a framework that is also suitable to nonlinear modelling. However, this framework has mostly confined itself
to applications involving single mediators assessed at a single time. The reason is that difficulties of identification tend to
pop up as confounders of themediator-outcome association are themselves affected by treatment. This happens in partic-
ular whenmultiple mediators are at play or repeatedlymeasuredmediators are assessed, for then the association between
(a given) mediator (at a given time) and outcomemay be confounded by other or previously measured assessments of the
mediator.
Mediation analyses are ideally based on repeated assessments of the mediator for each individual. This is because the
scientific interest typically lies in the effect of an exposure mediated via an entire mediator “process.” For example, the
interest in the LEADER trial lies in the effect mediated, regardless of the time at which the mediator of interest was
assessed. The indirect effect via a single assessment of the mediator is likely to capture only part of the indirect effect via
the mediator “process,” as it does not pick up the indirect effects through earlier or later instances of the mediator. The
absence of repeated mediator assessments therefore likely results in attenuation of the indirect effect.
When repeatedlymeasured assessments of themediator are available, it is tempting to consider simplifying the problem
ofmediation analysis by aggregating the longitudinal mediators to a single one (eg, in terms of some area under the curve,
or the last recorded glycated haemoglobin level). Such simplified mediation analyses may provide a useful starting point
but are difficult to justify as the final analysis for various reasons. As previously suggested, a single summary cannot usu-
ally capture the full complexity of the mediator, and this may lead to a weakening of the indirect effect. Such simplified
mediation analysis moreover prohibits adequate control for confounding. For instance, the area under the curve mea-
surements combine the repeated assessments of the mediator over time; this prohibits adequate control for confounding
because some of the covariate measurements measured during the study will then be both the cause and effect of the
obtained area under the curve, which typically has undesirable consequences.5 Basing the analysis on the last recorded
level of the mediator may appear to overcome this problem but is equally problematic. The reason is that the association
between the last recorded level of the mediator and the time-to-event endpoint is confounded by previously recorded lev-
els of the mediator; adjusting for these would be undesirable as it would eliminate part of the indirect treatment effect.
Furthermore, the last recorded level of the mediator may be influenced by the event time itself (whenever the mediator
is subject to a period effect), thereby inducing problems of reverse causality. In view of this, we will focus on approaches
that explicitly acknowledge the repeated measures nature of the mediator.
As previously suggested, the fact that the association between (a given) mediator (at a given time) and outcomemay be
confounded by previously measured assessments of the mediator typically complicates identification. The effect of expo-
sure on outcome as transmitted along a single pathway (eg, the effect via the first assessment of the mediator alone) is
however generally not of interest when themediator is repeatedlymeasured: the primary scientific interest then lies in the
effect via the “mediator process,” which is defined by a combination of pathways that involve the different assessments
of the mediator over time. Interestingly, closer examination of the identification results for mediation analysis clarifies
that the effect of exposure on outcome as transmitted along specific combinations of pathways (eg, involving different
or repeatedly measured mediators) is sometimes easier to identify.6 In this article, we will therefore make use of a gen-
eral theory of identification in nonparametric structural equations models with independent errors and possible latent
variables6 to infer the effect of exposure on outcome transmitted along a combination of pathways. In doing so, we will
address complications of working with a time-to-event endpoint, such as that individuals may die before the mediator is
assessed.
In the next section, we describe the setting under which we will work. In Section 3, we first discuss our proposal to
infer the direct and indirect effect of interest accounting for repeatedly measured mediators subject to time-varying con-
founding. We start with explaining how one may calculate these effects and end with a discussion of how the proposed
approach can be viewed as a generalisation of dynamic path analysis,7 as well as how it relates to alternative proposals.8-10
In Section 4, we present the method applied to the LEADER data and compare the results to less complex methods
(all variants of the common Cox regression model), and in Web Appendix B, we present a simulation study in order to
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evaluate the behaviour of our proposal. We conclude with some final remarks and ideas about possible extensions in
Section 5.
2 SETTING
Consider a study design that randomises independent patients i = 1, … ,n over two treatment arms Ai, coded 1 for treat-
ment and 0 for control, and intends to subsequently record longitudinal measurements of the mediator Mi1, … ,Mik at
visits 1, … , k, along with a time-to-event endpoint Ti. In actual fact, mediator measurements are only recorded until the
end-of-study time k or until the event of interest happens, whichever comes first. Our results will also be applicable to
nonrandomised exposures, as theywill accommodate adjustment for possible baseline confounding variables L0. Further-
more, the time-to-event endpoint may be censored administratively or due to loss to follow-up. We assume, for notational
convenience, that all patients are seen at the same, equidistant, time points. The latter restriction is readily relaxed (by
using time points ti1, … , tik), provided that these observation times are noninformative (and the no unmeasured con-
founding assumptions that we will assume, remain plausible). We moreover assume the absence of competing risks at
this point, which we will address in the discussion of this paper.
Informally, in relation to the example from the LEADER trial, our proposed analysis will infer how different the risk
of being event free at a given time would be in the liraglutide arm if the mediator levels for each patient in that arm
changed to the levels that we would have seen for that patient on the placebo arm; we will give a formal description
in Section 3. Because such mediation analysis conceptualises modifying the mediator, it will be important to control
for confounding of the association between mediator and outcome at each time. Our subsequent analysis, like nearly
all mediation analyses in the literature, assumes that sufficient data are available on prognostic factors of the event of
interest that are also associated with the mediator, to trust that sufficient control for confounding can be made. We will
use Li0,Li1, … ,Lik to denote those confounders (eg, concomitant medication, … ) measured for patient i at baseline and
at visits 1, … , k, respectively; Lit in particular includes the at-risk indicator I(T > t), which is 1 for subjects who are event
free at time t and 0 otherwise. Thus, Li0 refers to baseline covariates (eg, age, gender, baseline level of the mediator, … ),
and Li1, … ,Lik refer to potential confounders measured at visits 1, … , k, the same visits at which the mediator levels
were assessed. Importantly, we will assume throughout that those confounders Lit measured at visit t are not influenced
by the mediator level assessed at that time, although we will allow for those confounders to affect mediator levels at time
t (as well as at later times) and for them to have been influenced by mediator levels at earlier time points as in Figure 1.
When only previous confounder measurements are known to influence the mediator at visit t and the mediator at visit
tmay influence confounders at visit t and later times, then one must redefine Lit to include only covariates measured at
visit t − 1.
The causal diagram in Figure 1 visualises the data-generating mechanism that we will postulate, in the absence of
censoring (the additional complications posed by censoring of the event time will be addressed later). We will assume
throughout that it represents a nonparametric structural equation model with independent errors.11,12 It shows a clear,
prespecified causal ordering of the confounder and mediators over time, as considered in the works of VanderWeele and
Vansteelandt13 and Steen et al14 for cross-sectional multiple mediator settings. In spite of this, we will not adopt the pro-
posal by these authors for two reasons. First, it infers themediated effect via each of themediators at each time separately,
which gives a more refined decomposition than we are aiming for. Indeed, our interest lies in the effect mediated by
FIGURE 1 Causal diagram. Um and Ul refer to unmeasured variables.
The measured time-varying confounders L1 and L2 include survival at
visits 1 and 2 (T may thus be viewed as survival beyond visit 2). Besides the
assumptions embodied in this diagram, we assume that censoring at each
time is noninformative in each trial arm, given the history of measured
time-varying confounders and mediators at that time, in the sense defined
in the main text
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Mi1, … ,Mik, regardless of the specific time. In particular, we will infer the effect of randomised assignment to treatment
as transmitted along the combination of pathwayswhereby treatment directly influences one of themediatorsMi1, … ,Mik
(not via Li1, … ,Lik), which may in turn influence the risk of the event of interest through an arbitrary mechanism
(possibly via Li2, … ,Lik). Second, in their sequential approach, VanderWeele and Vansteelandt13 and Steen et al14 gener-
ally assume that themediators share no unmeasured common causes andmoreover assume that none of the intermediate
confounders shares unmeasured common causes with the outcome. We will relax these assumptions for two reasons.
First, to render the required no unmeasured confounding assumptions plausible, Li0,Li1, … ,Lik will likely include a large
number of covariates, some of which may be influenced by treatment. This makes it unlikely that all these components
are only associated with the endpoint of interest by means of a causal effect. In our development below, as in Figure 1,
we will therefore allow for the association between the covariates Li0,Li1, … ,Lik and the outcome to be itself confounded
by possibly unmeasured factors Ul. In fact, our proposal will also be valid when—unlike suggested by Figure 1—these
unmeasured factors are time varying and influenced by the history, including treatment. Second, it would be unlikely that
repeated assessments of the mediator for the same individual have no unmeasured causes in common. In our develop-
ment below, as in Figure 1, we will therefore allow for the association between the mediatorsMi1, … ,Mik to be affected
by possibly unmeasured factors Um. Traditional longitudinal mediation analyses,2 as well as dynamic path analysis that
can be viewed as an extension thereof to survival endpoints,7,15 implicitly assume the absence of such common causes
(or frailties)Ul andUm because they attempt a more refined decomposition of the exposure effect. They moreover invoke
Markov assumptions that assume the absence of long-term effects of covariates andmediators on covariates andmediators
measured later in time; such assumptions are easy to avoid in our proposed approach below.
Note that the mediated effect on which we will focus excludes pathways whereby treatment initially influences
time-dependent patient characteristics L, which then in turn influence the mediator and thereby the risk of the event.
Those pathways will be attributed to the indirect effect via those patient characteristics. This seems logical from an inter-
pretational point of view, but is also a more fundamental requirement: We will later see that the effect of treatment
transmitted along the combination of all pathways that intercept one or multiple mediators Mi1, … ,Mik (regardless of
where in the causal chain it intercepts these variables) cannot be identified withoutmaking overly stringent assumptions.
3 PROPOSAL
3.1 Estimands
To define the direct and indirect effects of interest, we will make use of the so-called path-specific effects,16 expressed
as differences or ratios of survival probabilities. In particular, we will calculate how likely it would be to be event free at
a chosen time t in the experimental treatment arm if the mediator levels for each patient changed to the levels that we
would have seen if that patient had been assigned to control, but the levels of the time-varying confounders had otherwise
remained unchanged. That is, the probability for a randomly chosen patient to be event free at time t on treatment if L1
took on the value L1(1) that we would have seen for that patient on treatment, if M1 were set to the level M1(0,L1(1))
that we would have seen on control for that patient if L1 had been set to the previously chosen value, if L2 were set to the
level L2(1,M1(0,L1(1))) that we would have seen on treatment for that patient if L1 andM1 had been set to the previously
chosen values, and so on (see the Appendix for more details). Let us denote the corresponding probability S1,0(t). When
repeating this for all times t, we obtain two survival curves, which one may contrast to visualise the targeted path-specific
effect via M. In particular, one may express it as the contrast S1,1(t)∕S1,0(t), S1,1(t) − S1,0(t), or {1 − S1,1(t)}∕{1 − S1,0(t)}
for each time t. One may additionally contrast S1,0(t) with how likely it is to be event free at that time in the control arm.
Let us denote this probability S0,0(t). If we repeat this for all times t, we will once more obtain two survival curves which
we may then contrast to visualise the path-specific effect not via M. In particular, one may express this as the contrast
S1,0(t)∕S0,0(t), S1,0(t) − S0,0(t), or {1− S1,0(t)}∕{1− S0,0(t)} for each time t. The mediated proportion can then be visualised
as the ratio of the path-specific effect viaM to the total intention-to-treat effect over time:
S1,1(t) − S1,0(t)
S1,1(t) − S0,0(t)
.
In the example from the LEADER trial, one may moreover have interest in contrasting S1,1(t) and S0,0(t) with S0,1(t), the
survival probability at time t in the control arm if the mediator levels for each patient changed to the levels that we would
have seen if that patient had been assigned to experimental treatment, but the levels of the time-varying confounders had
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otherwise remained unchanged. The methodology presented in this article can easily be applied to derive this contrast
as well.
One subtlety in the interpretation of S1,0(t) is that some patients may die sooner when assigned to control than when
assigned to experimental treatment, in which case their mediator values on control may appear ill defined until the con-
sidered time t.8 Note however that the variables Lt, t = 1, … , k, include the at-risk indicator I(T > t). SettingM1 to the level
M1(0,L1(1)),M2 to the levelM2(0,L1(1),M1(0,L1(1)),L2(1,M1(0,L1(1)))), … thus amounts to setting the mediators to the
level they would have taken in the control arm if the history of time-varying confounders, including the survival status
at that time, were set to the level on the experimental arm. We will discuss implications in more detail in the discussion
section (see also Web Appendix A).
In the forthcoming sections, we will explain how one may calculate the probabilities S1,0(t) for different times t. The
probabilities S1,1(t) and S0,0(t) can likewise be obtained upon reversing the codings 0 and 1 in the proposal below. They
could also be obtained directly from a standard nonparametric analysis of both treatment arms, although we recommend
calculating them in a model-based way as suggested below, to give results that are better comparable with the calculation
of S1,0(t). Our results in this section derive from the general identification results inWeb Appendix A. These identification
results can be obtained via application of the edge g-formula,17 which is a generalisation of the well-known g-formula to
the identification of the distribution of the so-called nested counterfactuals (or counterfactual responses to the so-called
edge interventions). The identification results are nonparametric, suggesting that arbitrary models can be used in each of
the stages. However, below, we will suggest the use of Cox regression models as a special case.
3.2 General procedure
In Web Appendix A, we show formally that the chance Sa,a∗ (t), for given values a and a∗, can formally be identified as
Sa,a∗ (t) =∫ 𝑓
(
T > t|T > ⌊t⌋,m⌊t⌋, l⌊t⌋,A = a)
×
⌊t⌋∏
s=1
𝑓
(
ms|T > s, ls,ms−1,A = a∗) 𝑓 (ls|T > s − 1, ls−1,ms−1,A = a) dmsdls,
where ⌊t⌋ is the visit time prior to (and including) time t, and we define ms ≡ (m1, … ,ms), ls ≡ (l1, … , ls), and m0 = ∅;
here, 𝑓 (ms|T > s, ls,ms−1,A = a∗) is shorthand notation for 𝑓 (Ms = ms|T > s,Ls = ls,Ms−1 = ms−1,A = a∗). Specialising
this to times t between the first and second mediator assessments and noting that L1 is composed of the at-risk indicator
I(T > 1) and patient characteristics V1, the chance S1,0(t) can formally be calculated as
∫ P(T > t|T > 1,A = 1,m1, v1, l0)𝑓 (m1|T > 1,A = 0, v1, l0)
× 𝑓 (v1|T > 1,A = 1, l0)P(T > 1|A = 1, l0)𝑓 (l0)dm1dv1dl0. (1)
The above identification results show some similarity to the g-formula and themediational g-formula,18 but do not follow
from those theories, which apply to nonnested counterfactuals only.
Monte Carlo integration can be used for evaluating the above identity and, moreover, gives it intuitive meaning. This
involves first fixing L0 for each individual i = 1, … ,n at the observed value l0i. Next, for each individual, a (possibly
counterfactual) event time ti(1) is drawn from the distribution f(t|A = 1, l0i), and next for individuals with ti(1) > 1, the
counterfactual level V1(1) is fixed at a random draw v1i(1) from the distribution f(v1|T > 1,A = 1, l0i). Subsequently, for
each individual with ti(1) > 1,M1(0,L1(1)) is fixed at a random draw m1i(0, l1i(1)) from the distribution f(m1|T > 1,A =
0,V1 = v1i(1), l0i), and T(1,L1(1),M1(0,L1(1))) is fixed at a random draw ti(1, l1i(1),m1i(0, l1i(1))) from the distribution
f(t|T > 1,A = 1,M1 = m1i(0, l1i(1)),V1 = v1i(1), l0i); for each individual with ti(1) ≤ 1, ti(1, l1i(1),m1i(0, l1i(1))) is fixed at
ti(1). The chance S1,0(t) can then be estimated as the proportion of individuals with ti(1, l1i(1),m1i(0, l1i(1))) > t.
Themain drawback of the aboveMonte Carlo strategy is that it involves modelling the joint distribution of all variables,
which becomes especially cumbersome when L1 is high dimensional. Upon rewriting (1) in terms of a series of nested
conditional expectations,
E(E[E{P(T > t | T > 1,A = 1,M1,L1,L0) | T > 1,A = 0,L1,L0} | T > 1,A = 1,L0] × P(T > 1 | A = 1,L0))
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Patient Ai L0i L1i M1i Ei Ti Q𝟏i (t) Q
𝟏
mi(t) Q
𝟎
li(t) Q
𝟎
i (t)
1 0 62.79 62.36 63.36 1 5.57 0.81 0.79 0.82 0.98
2 0 64.75 65.96 75.78 1 0.65 . . 0.82 0.97
3 0 57.13 56.35 74.80 1 11.44 0.77 0.80 0.83 0.98
4 1 56.28 55.27 53.08 1 9.42 0.84 0.80 0.83 0.98
5 1 72.55 68.05 59.07 1 13.68 0.85 0.82 0.82 0.97
6 1 67.61 61.02 54.17 1 9.61 0.87 0.84 0.82 0.98
7 0 52.84 46.85 65.93 1 6.70 0.84 0.84 0.83 0.98
8 1 65.16 58.16 51.88 0 24.00 0.88 0.84 0.82 0.97
9 0 62.69 59.91 66.51 1 5.61 0.82 0.81 0.82 0.98
10 1 74.23 65.88 50.62 0 24.00 0.89 0.85 0.82 0.97
TABLE 1 A toy example for a restricted set of
patients
(in line with a common representation of the g-formula), repeated regressions can be used instead (see Web Appendix A
for more detail). We will illustrate this for the data structure in Table 1, which shows artificial data for 10 patients; here,
Ei is an indicator for the event (1 if the event occurred while enrolled in the trial, 0 otherwise).
In particular, at each time t, the chance S1,0(t) can be calculated as follows.
1. Fit a Cox regression model among people who survived the previous visit in the experimental arm in function
of the history of mediators and confounders up to that visit, accounting for censoring in the default way. This
analysis accommodates noninformative censoring, given the history of measured mediators and confounders up
to the considered visit. Next, use the fitted model to predict the chance of surviving the given time t for each
patient in the study who survived the previous visit, setting the mediators and confounders to their observed
values. Denote the result Q⌊t⌋i (t) for patient i. Besides maximum partial likelihood estimators of the regression coef-
ficients, this requires an estimator of the cumulative baseline hazard, for which we used the Breslow estimator.
For instance, with parameter estimates ?̂?1 = 0.02, ?̂?2 = 0.05, and ?̂?3 = −0.05 for the log hazard ratio correspond-
ing to M1,L0, and L1, respectively, the chance of surviving the given time t (eg, 5 months) for the first patient is
exp[−Λ̂0(5) × exp{(0.02 × 63.36) + (0.05 × 62.79) + (−0.05 × 62.36)}], with Λ̂0(5) the estimated cumulative baseline
hazard, which equalled 0.06 after 5 months.
2. Next, repeat the following for each of the previous visits k = ⌊t⌋ to 1.
(a) Regress Qk(t) on the history of the mediators M̄k−1 = (M1, … ,Mk−1) and the history of the covariates L̄k =
(L0, … ,Lk) among people who were event free at visit k in the control arm. BecauseQk(t) lies between 0 and 1, a
quasi-binomial regression with logit link may be an appropriate choice. Next, we can use the model to calculate
a prediction Qkm(t) for all subjects who were event free at visit k, based on their observed data on mediators and
confounders. For instance, with parameter estimates 𝛽0 = 1.48, 𝛽1 = 0.049, and 𝛽2 = −0.051 for the intercept and
the log odds ratios corresponding to L0 and L1, respectively, the prediction Qkmi(t) for k = 1 for the first patient
who was event free at the first visit would be calculated as expit{1.48+ (0.049 × 62.79) + (−0.051 × 62.63)} and
would equal 0.79.
(b) RegressQkm(t) on the history of mediators M̄k−1 and confounders L̄k−1 among people who were event free at visit
k in the experimental treatment arm. Because Qkm(t) lies between 0 and 1, a quasi-binomial regression with logit
linkmay be an appropriate choice. Use themodel to calculate a predictionQk−1l (t) for all patients whowere event
free at visit k − 1, based on their observed data on mediators and confounders. For instance, with parameter
estimates 𝛿0 = 1.71 and 𝛿1 = −0.003 for the intercept and the log odds ratio corresponding to L0, the prediction
Qk−1li (t) for k = 1 for the first patient is expit{1.71 + (−0.003 × 62.79)} and equals 0.82. Note that Q
k−1
l (t) is now
also estimated for patients who were not event free at visit k, using their data on M̄k−1 and L̄k−1.
(c) Fit a Cox model among people who were event free at visit k− 1 in the experimental treatment arm, in function
of the history M̄k−1 and L̄k−1. Use the fitted model to estimate the chance of surviving visit k for each patient in
the study who was event free at visit k − 1, setting M̄k−1 and L̄k−1 to the observed covariate values. Let Qk−1(t)
denote the product of this predicted value and the value of Qk−1l (t) obtained in the previous step. For instance,
with the following parameter estimate for the log hazard ratio, ?̂?1 = 0.003, the probability of being event free at
the first visit on the experimental treatment is calculated as exp[−Λ̂0(3)×exp{0.003 × 62.79}] for patient 1, with
Λ̂0(3) the estimated cumulative baseline hazard, which equalled 0.02 after the first visit.
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3. When the previous steps have been repeated for visits k = ⌊t⌋ to 1, then average the value Q0(t) obtained in the
final step across all patients. The resulting average is an estimate of S1,0(t). Averaging Q0(t) across all patients in the
example would thus result in an estimate of S1,0(t) at 5 months, which equals 0.80.
Note that step 2(a) involves regressing predictions among patients who were event free in the control arm (in order
to integrate over the distribution of the mediator), whereas step 2(b) involves regressing predictions among patients
who were event free in the experimental treatment arm (in order to integrate over the distribution of time-varying
confounders). This differential selection of patients in the respective steps is reflective of the “construction” of nested
counterfactuals.
In the above procedure, we have chosen to use separate Cox models at each time at which intermediate variables are
assessed. Under correct specification of these models, the required censoring assumption is that censoring at each study
visit k is noninformative, in the sense that the decision to discontinue the trial at a given time has no residual dependence
on the remaining survival time amongst (alive and participating) patients in the same trial arm with the same history
of the observed measurements M̄k and confounders L̄k at that time. Alternatively, one may choose to obtain predictions
from a Cox model with time-varying covariates and avoid the need for separate Cox regression models at each visit time.
This approach has the advantage of yielding potentially more precise predictions as this Cox regression model is fitted on
the whole sample. The disadvantage however is a greater risk of misspecifying this Cox regression model. In the above
procedure, we could alternatively have used parametric survival models using splines for the time effect19 or binomial
regression models for the chance of surviving time t, separately for each time t. We have not considered the latter option
because the information may become sparse at the later time points, which does not pose complications when relying on
the proportional hazards assumption in the Cox regression model.
For computational convenience and to limit the modelling efforts, we have chosen to use binomial regression models
to model the predictions obtained from the Cox model. One concern about this strategy is that the considered bino-
mial regression model may fail to be congenial with the chosen Cox model. In view of this, we recommend the use of
quasi-binomial regression with a logit (as opposed to probit) link. The use of such models ensures that when the above
procedure is employed for the calculation of S0,0(t) or S1,1(t), misspecification (and in particular lack of congeniality) of
the logistic regression models for Qkm(t) and Qkl (t) does not induce bias because the average of the fitted values from a
logistic regression model (in the treatment or control arm) equals the average of the outcome under that model (in the
treatment or control arm), regardless of whether the model is correctly specified.20 To additionally ensure unbiased esti-
mation of S1,0(t) or S0,1(t), we further recommend that these logistic regression models obey the structure of the models
that were used to obtain the predictions which they use as input. For instance, if the Cox model contains interactions
between A and Lk, then these should also be included in the logistic regression model for Qs(t), s < k; if the Cox model
contains interactions between A andMk, then these will likely give rise to interactions between A and predictors ofMk in
the logistic regression model for Qs(t), s < k.
3.3 Dynamic path analysis
The proposed approach can be viewed as a generalisation of dynamic path analysis,7,15 which itself extends linear struc-
tural equation analysis to additive hazardmodels and normally distributedmediators, which obey additive linear models.
To see this, we first consider a setting with a single mediator and no confounders for pedagogic purposes. Assuming an
additive hazard model21 for the time-to-event outcome
𝜆(t|A,M1) = 𝜆0(t) + 𝜆1(t)A + 𝜆2(t)M1I(t > 1)
and a linear regression model for the mediator
E(M1|T > 1,A) = 𝛼0 + 𝛼1A,
with normal errors and constant variance 𝜎2, we can evaluate expression (1) as follows. First, because the survival prob-
ability at time t is exp{−H(t)}, with H(t) the cumulative hazard at time t, the survival probability P(T > t|T > 1,A,M1)
can be evaluated as exp{−ΔΛ0(t) − ΔΛ1(t)A − ΔΛ2(t)M1} with ΔΛj(t) = Λj(t) − Λj(1) and Λ𝑗(t) = ∫ t0 𝜆𝑗(s)ds for j = 0, 1, 2
the cumulative hazard. Second, using that the moment generating function E{exp(Zt)} of a normal variate Z ∼ N(𝜇, 𝜎2)
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equals exp(𝜇t + 𝜎
2t2
2 ), integrating outM1 in expression (1) yields
exp
{
−ΔΛ0(t) − ΔΛ1(t) − ΔΛ2(t)E(M1|T > 1,A = 0) − ΔΛ2(t)22 Var(M1|T > 1,A = 0)
}
,
which equals
exp
{
−ΔΛ0(t) − ΔΛ1(t) − ΔΛ2(t)𝛼0 −
ΔΛ2(t)2
2 𝜎
2
}
.
Finally, multiplying this result with P(T > 1|A) = exp{−Λ0(1) − Λ1(1)A} yields
P(T1,0 > t) = exp
{
−Λ0(t) − Λ1(t) − ΔΛ2(t)𝛼0 −
ΔΛ2(t)2
2 𝜎
2
}
.
Likewise,
P(T0,0 > t) = exp
{
−Λ0(t) − ΔΛ2(t)𝛼0 −
ΔΛ2(t)2
2 𝜎
2
}
P(T1,1 > t) = exp
{
−Λ0(t) − Λ1(t) − ΔΛ2(t)𝛼0 − ΔΛ2(t)𝛼1 −
ΔΛ2(t)2
2 𝜎
2
}
,
from which at each time t, the path-specific effect not viaM and viaM can be calculated in terms of survival probabilities
as
PDE(t) =
S1,0(t)
S0,0(t)
= exp{−Λ1(t)}
and
PIE(t) =
S1,1(t)
S1,0(t)
= exp {−ΔΛ2(t)𝛼1} = exp {−(Λ2(t) − Λ2(1))𝛼1} ,
respectively, for t > 1 and 1 for t ≤ 1. These expressions hold more generally for studies with multiple waves if the
event time obeys an additive hazard model at each time (conditional upon the information observed until that time) and
the mediator in each wave of the study obeys a normal linear regression model with additive effects, constant variance,
and normal errors. Similar expressions are also used in dynamic path analysis.7 The only difference lies in the indirect
effect that has the additional term Λ2(1) × 𝛼1 in our proposal. This shows a first limitation of dynamic path analysis as
currently considered in the work of Strohmaier et al7 in that this strategy ignores the potential for the event happening
prior to the mediator assessment of the first wave. If all patients survive till the first mediator measurement, as in the
examples in the work of Strohmaier et al,7 Λ2(1) equals zero and the approaches will coincide. As such, our results give
formal justification for the expressions considered in dynamic path analysis as expressing path-specific effects under the
above listed assumptions. They also signal the other limitations of dynamic path analysis in that it is limited to specific
additive models for the event time and themediators, and that it cannot (easily) accommodate time-varying confounders,
nor lagged effects of the mediators.
4 EXAMPLE FROM THE LEADER TRIAL
LEADER was a multicentre, international, randomised, double-blind clinical trial evaluating liraglutide (A = 1) against
placebo (A = 0), both added to the standard of care. The trial was designed in accordance with guidance from FDA22
regarding the evaluation of cardiovascular risk for new antidiabetic therapies. In total, 9340 patients with type II diabetes
at high risk for cardiovascular disease were randomised to one of the two treatment groups with a median follow-up
time of 3.8 years (ranging 3.5-5.0 years). The subjects were attending planned visits 3 months after randomisation and
subsequently every 6 months hereafter where at least HbA1c (M) was measured. The primary endpoint was the time T
from randomisation to first occurrence of a so-called major cardiovascular event (MACE) defined as nonfatal myocardial
infarction, nonfatal stroke, or cardiovascular death. A firstMACEoccurred in significantly fewer patients in the liraglutide
group (13.0%) than in the placebo group (14.9%) corresponding to an estimated hazard ratio of 0.87 (95% CI [0.78; 0.97];
P = 0.01) in the prespecified primary analysis, which was a Cox regression model with treatment as the only fixed effect.
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FIGURE 2 Estimated HbA1c levels over
time by treatment group. EOT, end-of-trial
visit (time varies by subject) [Colour figure
can be viewed at wileyonlinelibrary.com]
FIGURE 3 Estimated probabilities
S1,0(t), S1,1(t), and S0,0(t) [Colour figure can
be viewed at wileyonlinelibrary.com]
Significant positive effects of liraglutide vs placebo were also found on cardiovascular risk factors such as glycated
haemoglobin (HbA1c), bodyweight, urinary albumin to creatinine ratio, and blood pressure, and the interest is to evaluate
to what extent these potential pathways might explain liraglutide's protective effect on cardiovascular events. The main
results from the study can be found in the work of Marso et al.1
To illustrate the proposed approach formediation analysis, we shall here restrict the attention to the potentialmediation
on the primary endpoint via the effect of liraglutide onHbA1c levels. Throughout,wewillmoreover assume that censoring
is noninformative in the sense that the time to first MACE is equally distributed in patients who do versus those who do
not discontinue the trial at a given time, but were assigned to the same arm and have the same history of HbA1c at that
time. In Figure 2, themeanHbA1c levels over time are shown, as estimated by amixedmodel for repeatedmeasurements
with adjustment for baseline covariates. As reported in the work of Marso et al,1 the estimated treatment difference was
−0.40 percentage points (95% CI [−0.45; −0.34]) at the 36-month visit, which was the last scheduled visit with laboratory
testing for the entire trial population. In Figure 3, the estimated survival curves S1,0(t) are shown along with S1,1(t) and
S0,0(t). The survival curves were estimated in accordance to the method presented in Section 3, where HbA1c measured
after 3, 6, 12, 18, 24, 30, and 36 months, respectively, were included as mediators. Due to the novelty of the results, we
could not present analyses that additionally adjusted for confounders other than supplementary HbA1c measurements,
eg, body weight, and insulin use. Therefore, the results (which are also based on models with additive effects) are only to
be considered hypothesis generating and should be interpreted with caution. The proposedmethod provides a framework
for further analyses that can adjust for various confounders and explore other potential pathways than glycaemic control
represented by HbA1c. More exhaustive analyses are reserved for subsequent communication in a medical journal.
Figure 4 visualises the estimated mediated proportions at each visit. Inference was based on the nonparametric boot-
strap with 1000 resamples. The results indicate that HbA1c is mediating parts of the effect of liraglutide on time to first
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FIGURE 4 Mediated proportions for
time to first major adverse cardiovascular
event with longitudinal HbA1c levels as
mediators
MACE. Note however that the estimates of themediated proportions are subject to uncertainty (reflected in the wide con-
fidence intervals), and potentially residual confounding bias. Moreover, the mediated proportion appears to grow over
time, whereas the total effect as measured by the hazard ratio is constant. This may suggest that the way by which gly-
caemic control represented byHbA1c biologically influences the cardiovascular riskmay be complex. For instance, it may
be the case that the mediated proportion over time depends on the number of available HbA1c measurements that are
included in the analysis. Nearly identical results were found when body weight, urinary albumin to creatinine ratio, and
systolic blood pressure were considered as additional potential mediators (not shown).
As a comparison to themethod presented in Section 3, three relatively simple mediation analyses were also conducted:
1. Change in HbA1c after 6 months was used as mediator and included as a covariate in a Cox regression model with
treatment as fixed factor, and baseline HbA1c as additional covariate.
2. Change in HbA1c over time was used as mediator and included as a time-dependent covariate in a Cox regression
model with treatment as fixed factor and baseline HbA1c as additional covariate.
3. Change in the trapezoidal area under the HbA1c curve divided by time (updated mean) was used as mediator and
included as a time-dependent covariate in a Cox regressionmodel with treatment as fixed factor and baselineHbA1c
as additional covariate.
For all three models, the mediated proportion was calculated as the difference in log hazard ratios between the models
without and with the mediator, respectively, divided by the log hazard ratio from the model without the mediator. The
results, which can be found in Table 2, are included because they represent rather standard analyses, even though they are
known to be biased. Analyses 1 and 3 indicate somemediation. However, note that these mediated proportions have been
calculated on different scales and are difficult to interpret because they reduce the mediator process to a single summary
and, partly as a result, do not properly adjust for time-varying confounding by the mediator history. As pointed out in
Section 1, mediation analyses based on a single summary measure of the mediator may result in an underestimation of
the mediated proportion, and this could very likely be the explanation for these differences. Furthermore, analysis 2 does
not indicate any clear mediation, which is in line with the expectation that an analysis based on the last recorded value
Model Hazard ratio 95% CI Mediated proportion
MACE primary analysis 0.87 (0.78; 0.97)
Six-month HbA1c change from the baseline 0.92 (0.81; 1.04) 0.40
as time-fixed covariate
HbA1c change from baseline 0.88 (0.79; 0.99) 0.08
as a time-dependent covariate
Updated mean of HbA1c 0.92 (0.82; 1.03) 0.40
as a time-dependent covariate
Abbreviation: MACE, major adverse cardiovascular event.
TABLE 2 Results from three
simple mediation analyses
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of the mediator will eliminate parts of an existing indirect effect. In addition, this analysis ignores confounding by the
history of the mediators.
5 DISCUSSION
In this paper we have proposed a strategy to infer the effect of a randomised treatment on a time-to-event outcome
as transmitted along the combination of pathways, whereby treatment directly—other than through a sufficient set of
time-varying confounders—influences one of a sequence of repeatedly measured mediator measurements Mi1, … ,Mik,
which in turn influence the risk of the event of interest through an arbitrary mechanism. This proposal builds on the
general theory on identification of path-specific effects in nonparametric structural equations models with independent
errors.6 It can be considered as a generalisation of the structural equation models extension to time-to-event outcomes,
the so-called dynamic path analysis,7 but can be used in more realistic settings as it can handle events happening prior to
the first assessment of the mediator, is not limited to specific additive models for the event time andmediators, and easily
accommodates time-varying confounders and long-term effects of mediators and covariates. As the general identification
results in Web Appendix A are nonparametric, arbitrary models can be used in each of the steps of the procedure and
our proposal is thus not limited to time-to-event outcomes. With a continuous outcome for instance, the Cox regression
models at each wave would be replaced with a single model for the mean outcome at time t. Limited simulation stud-
ies in Web Appendix B demonstrate the adequate performance of the proposed methodology. SAS code for running this
analysis is available in the online Supplementary Materials.
Our results shed light on the subtle interpretation of direct andmediated effects in studieswith time-to-event endpoints.
The notion of a direct effect conceptualises fixing the level of the mediator in the experimental treatment arm as it would
have been on the control arm, but if a patient would have lived longer on the experimental treatment arm, then it becomes
vague at what level the mediator ought to be controlled. For that reason, we have considered fixing the mediator at the
level that would have been seen on the control arm if the patient had been kept alive for the same duration as in the
experimental arm. In some cases, one may well hypothesise what would have happened if an event such as death had
been prevented. For instance, if one of the study participants dies in a car crash, then we may well consider what that
person's mediator level would have been at a given time had the car crash been prevented. In other cases, this is much
harder to conceptualise. For instance, it is more difficult to imagine interventions that would prevent the event of interest
in the considered patient populations. Strictly speaking one does not need to be precise about the kind of underlying
interventions as inferences apply to all interventions that are noninvasive in the sense that if they had been applied
to individuals who remained event free, the same data for the mediator would have been observed. However, it does
complicate interpretation in the same way as treatment effects can be difficult to interpret in the presence of drop-out due
to death.23
A simple fix to the above problem can be made in extreme cases where treatment is beneficial for all patients. In that
case, S0,1(t) is always well and unambiguously defined, and thus one can use the contrast of S0,1(t) and S0,0(t) as a measure
of indirect effect, and the contrast of S1,1(t) and S0,1(t) as a measure of direct effect. Alternatively, andmore generally, note
that expression (1) can also be interpreted as a so-called (randomised) interventional effect.24 In particular, as in the work
of Zheng and van der Laan,9 it can be interpreted as the chance of being event free at time t if all patients were randomised
to liraglutide and at each time s < t, the mediator were randomly drawn from the distribution of the mediator in patients
in the control arm who survived time s and have the same history of covariate data (as observed under the considered
regime). One potential concern here is that patients who survive time s on the control armmay fail to be comparable with
those who survive time s on the intervention arm, even after adjusting for the history of time-varying covariates. This
may well happen as a result of survivor bias, due to which surviving patients may become more and more selective as
time goes by. In our proposal, we have excluded this possibility by assuming the absence of unmeasured common causes
of mediator (eg, M1) and time-varying confounders (eg, L1) in the causal diagram of Figure 1. Such assumptions tend
not to be spelled out in the existing approaches for (randomised) interventional direct and indirect effects. In addition,
Didelez10 proposes related estimands. These estimands are well-defined, even when patients on the control arm tend to
experience events sooner than those on the intervention arm. They are moreover identifiable under weaker assumptions
than the considered path-specific effects, as they are not defined in terms of cross-world counterfactuals, but have not
been formally extended to settings with confounding by time-varying covariates.
Our proposed approach is thus related to the works of Zheng and van der Laan9 and Didelez,10 but in contrast to these,
focuses on the identification of path-specific effects. VanderWeele and Tchetgen Tchetgen18 also adopted interventional
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direct and indirect effects, but they consider random draws from the distribution of the mediator at a certain exposure
level conditional on only baseline covariate data. Their indirect effect, unlike ours, thus includes pathways whereby the
treatment influences time-varying confounders, then in turn influences themediator and via that also the outcome. Their
proposal also has the disadvantage that draws from the mediator distribution are ill defined when patients may die dur-
ing the study. Lin et al8 handled this problem by redefining nested counterfactuals to include a counterfactual survival
status in a similar way as in our proposal; in doing so, they eliminate pathways whereby treatment influenced the media-
tor via survival from the indirect effect, as in our proposal. However, in contrast to the work of Zheng and van der Laan9
and our proposal, they do not consider random draws from the mediator distribution conditional on time-varying con-
founders. This raises questions whether the values drawn for a given patient will be sufficiently representative for what
that patientmight have “naturally” experienced,making these estimands less suitable to develop insight intomechanism.
For instance, the assessment of a direct effect demands fixing the mediator at subject-specific levels and it is unlikely that
these can be “predicted” well when only baseline confounders are used for prediction.
Zheng and van der Laan9 deemed the assumptions needed to infer the path-specific effects withmultiplemediators and
time-varying confounders too strong for the purpose of effect mediation in a survival study. InWeb Appendix A, we argue
that following the arguments of Shpitser6 and the recanting witness criterion,16 the path-specific effects represented by
the causal diagram of Figure 1, are identified if (a) the exposure A is randomly assigned, (b) all common causes of the
time-to-event outcome and themediator at each time aremeasured, and (c) that this causal diagram represents a nonpara-
metric structural equationmodel with independent error terms.12,25 In particular, thismeans that the only variation in the
variables (and their counterfactual values) on the causal diagram (not explained by previous variables in the diagram) is
due to mutually independent error terms. Assumption (b) further implies that unmeasured common causes of the medi-
ators over time are allowed (as long as they do not directly influence the time-to-event outcome), as well as unmeasured
common causes of baseline and time-varying confounders and the time-to-event endpoint. Note that common causes of
time-varying confounders and mediators are not allowed to be unmeasured.
The above results ignored competing risks due to death from noncardiovascular causes because the adjusted
(Aalen-Johansen) cumulative incidence curves were almost identical to the Kaplan-Meier curves, suggesting that no
appreciable differences can be expected when accounting for competing risks. However, the proposed approach can rela-
tively easily be extended to handle competing risks. In that case, in each step of the algorithm,we substitute the probability
of being event free by time t by the probability of being either event free by time t or having experienced a competing event.
The latter can be calculated either by combining the results from standardCox regressionmodels for the two cause-specific
hazards for both causes,26 or using binomial regression models for the cumulative incidence. Another obvious extension
to the above proposal is settings where the mediator is multivariate at each time, as may be the case when examining the
effect mediated via, eg, glycated haemoglobin and body weight. It then infers the effect of treatment mediated via at least
one of those mediators. This does not render the procedure any more complicated, in the sense that it requires no addi-
tional modelling. The above procedure also readily extends to enable decomposition of the treatment effects via multiple
mediators. For instance, consider two mediatorsM(1)t andM
(2)
t , and a vector of covariates L∗t at each time t = 1, … , k, and
suppose thatM(1)t may influenceM
(2)
t , but not vice versa. Suppose furthermore that L∗t may influenceM
(1)
t andM
(2)
t , but
not vice versa. Then, one may use the above procedure withMt ≡ M(2)t and Lt ≡ (M(1)t ,L∗t ) to infer the effect of treatment
mediated viaM(2)t for t = 1, … , k. One may likewise use the above procedure withMt ≡ M(1)t and Lt ≡ (M(2)t−1,L∗t ) to infer
the effect of treatment mediated viaM(1)t for t = 1, … , k. When both effects are expressed on the risk difference scale, one
may subtract the sum of both effects from the total effect S1,1(t) − S0,0(t) to obtain the direct treatment effect, which is not
mediated by eitherM(1)t orM
(2)
t , t = 1, … , k.
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